SavedAdd your journal

Journals / Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi / 2007 / Cilt: 4 - Sayı: 2

Comparison of crinone and 17-hydroxyprogesterone caproate for luteal support following intrastoplasmic sperm injection and embryo transfer

İntrastoplazmik sperm enjeksiyonu ve embryo transferini takiben luteal destek için crinone ve 17-Hidroksiprogesteron kaproatın karşılaştırılması

NURAY BOZKURT
Mustafa BAŞARAN
Hakan YARALI
Pages
114–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It can be said that luteal phase support through vaginal administration is an effective and tolerable method.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to compare an intramuscular alternative, 17α-hidroxyprogesterone caproate with vaginal Crinone 8%, both of which are used for luteal support following ICSI and ET.
📊
Key Findings & Data:Sixty- three patients were supplemented with Crinone 8% (90 mg once daily) and 209 patients with 250 mg 17-hydroxyprogesterone caproate (Proluton) every four days starting on the day after oocyte retrieval.
💡
Conclusion & Impact:It can be said that luteal phase support through vaginal administration is an effective and tolerable method.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:17-alfa-hidroksiprogesteron · Sperm enjeksiyonu · intrasitoplazmik

Abstract

Objective: This study aimed to compare an intramuscular alternative, 17α-hidroxyprogesterone caproate with vaginal Crinone 8%, both of which are used for luteal support following ICSI and ET. Study Design: Two hundred seventy-two patients undergoing ICSI and ET were included. Sixty- three patients were supplemented with Crinone 8% (90 mg once daily) and 209 patients with 250 mg 17-hydroxyprogesterone caproate (Proluton) every four days starting on the day after oocyte retrieval. Positive βhCG, clinical pregnancy, and implantation and abortion rates were compared among these groups. Results: In women undergoing ICSI and ET, once a day progesterone supplementation with Crinone beginning the day after oocyte retrieval results in comparable pregnancy, implantation and abortion rates with women supplemented with i.m. 17-hydroxyprogesterone caproate. Conclusion: The results of vaginal progesterone administration were similar to the results obtained after intramuscular 17-HPC, which is taught to have similar effects with daily intramuscular progesterone and offered as an alternative for it, administration. It can be said that luteal phase support through vaginal administration is an effective and tolerable method.

Özet

Amaç: Bu çalısmada alternatif bir intramuskuler progesteron olan 17α-hidroksiprogesteron kaproat (17-HPC) ile vaginal Crinone %8'in ICSI ve ET'ni takiben luteal destek için kullanılmasının karşılaştırılması amaçlanmıştır. Materyal-Metod: Çalışmaya ICSI ve ET yapılan ikiyüz yetmiş iki hasta dahil edildi. Oosit toplanmasının ertesi gününden baslayarak 63 hastaya Crinone %8 (90 mg günlük) ve 209 hastaya her dört günde bir 250 mg 17-hydroksigesterone kaproat (Proluton) verildi. BhCG pozitifligi, klinik gebelik, implantasyon ve abortus oranları iki grup arasında karşılastırıldı. Sonuçlar: ICSI ve ET yapılan kadınlarda oosit toplanmasının ertesi günü baslanarak günde bir kere Crinone verilmesi, i.m. 17- hydroksiprogesteron kaproat verilmesi ile benzer gebelik, implantasyon ve abortus oranları sağlanmıstır. Yorum: Vaginal progesteron desteği sonuçları, günlük intramuskuler progesterona benzer etkide olduğu düşünülen ve ona bir alternatif olarak önerilen intramuskuler 17-HPC desteğinden sonra elde edilen sonuçlarla benzerdir.Vaginal yolla progesteron desteği efektif ve tolere edilebilen bir metoddur.

🔖

Cite This Article

BOZKURT, N., BAŞARAN, M., YARALI, H. (2007). Comparison of crinone and 17-hydroxyprogesterone caproate for luteal support following intrastoplasmic sperm injection and embryo transfer. Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi, Cilt: 4 - Sayı: 2, 114–120. https://ajindex.com/articles/320556

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Edward R.G., Steptoe P.C.: Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br J Obstet Gynaecol. 1980;87:737-56
  2. Smitz J., Erard P, Camus M, Devroey P, Tournaye H, Wisanto A.et al.: Pituitary gonadotropin secretory capacity during the luteal phase in superovulation using Gn-RH agonist and HMG in a desensitization or flare-up protocol. Hum Reprod. 1992; 7:1225-9
  3. Smitz J., Bourgain C., Van Waesberghe L., Camus M., Devorey P.: Van Steirteghem A. C. A prospective randomized study on oestrediol alerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum Reprod. 1993;8:40-5
  4. Soliman S., Daya S., Collins J., Hughes E.G.: The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril. 1994;61:1068-76
  5. Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynecol Scand. 2001; 80:452-66
  6. Loredana C, Sandro G, Claudio M et al. A prospective randomized study comparing intramuscular progesterone and 17-hydroxy- progesterone caproate in patients undergoing in vitro fertilization- embryo transfer cycles. Fertil Steril 2001; 76:394-396
  7. Posaci C., Smitz J., Camus M., Osmanagaoglu K., Devroey P.: Progesterone for the luteal support of assisted reproductive technologies: clinical options. Human Reprod. 2000;15:129- 148
  8. Smitz J, Devroey P., Camus M. et al.: The luteal phase and early pregnancy after combined GnRH- agonist/HMG treatment for superovulation in IVF or GIFT. Human Reprod. 1998;3:585- 590
  9. Smith E.M., Anthony F. W., Gadd S.C. et al.: Trial of support treatment with human chorionic gonadotropin in the luteal phase after treatment with buseralin and human menopausal gonadotropin in woman taking part in an in vitro fertilization programme. Br Med J. 1989;1483-1486
  10. Belaisch-Allart J., De Mouzon J., Lapousterle C. et al.: The effect of HCG supplementation after combined GnRH agonist/ HMG treatment in an IVF programme. Human Reprod. 1990;5: 163-166
  11. Albano C., Grimbizis G., Smitz J., Riethmüller-Winzen H., Reissman T., Van Steirteghem A. et al.: The luteal phase of nonsuplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357-9
  12. Smitz J, Devroey P, Faguer B et al. Aprospective randomized comparison of intramuscular or intravaginal n